Hepatocellular carcinoma
Conditions
Interventions
Miriplatin-lipiodol suspension group:Powdered miriplatin(70mg) suspended in lipiodol(6ml) is injected through the catheter selectively introduced into the hepatic artery,The doses of suspension are de
Sponsors
First Department of Internal Medicine,Gifu University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Histologically or clinically comfirmed Hepatocellular carcinoma 2)Patients diagnosed as stage2-3 3)Interval of 4 weeks or over between last treatment and present therapy 4)Child-pugh is A or B 5)No indication for surgical resection or local ablation 6)PS is 0,1 or 2 7)Sufficient functions of main organ(bone marrow,kidney,heart)and conditions filled a following criteria 1 WBC>=2,000 /mm3,<=10,000 /mm3 2 Plt>=50,000 /mm3 3 Hb>=8.0 g/dL 4 T-Bil<=3.0 mg/dL 5 PT>=50% 6 Creatinine<=1.5 mg/dL 7 BUN<=35 mg/dL 8)Age is more than 20 years old and below 80 years old 9)Patients obtained written infoemed consent
Exclusion criteria
Exclusion criteria: 1)Patienta with sever co-morbidity such as cardiac failure or renal failure 2)Patienta with a medical history of severe hypersensitivity 3)Patients who are pregnant,lactating or are suspected to be a pregnant 4)Patients who are concluded to be inappropriate to participate in this study by their physitians
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival Safety | — |
Countries
Japan
Contacts
Public ContactKoji Takai
Gifu University Hospital First Department of Internal Medicine
Outcome results
None listed